Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Acquires $407,691.81 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc acquired 15,321 shares of the company’s stock in a transaction dated Friday, March 27th. The stock was acquired at an average cost of $26.61 per share, for a total transaction of $407,691.81. Following the completion of the purchase, the insider directly owned 142,360 shares in the company, valued at $3,788,199.60. This trade represents a 12.06% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total value of $23,629.68.
• On Monday, March 30th, Millennium Management Llc acquired 9,533 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $25.86 per share, for a total transaction of $246,523.38.
• On Thursday, March 26th, Millennium Management Llc purchased 5,731 shares of Sensei Biotherapeutics stock. The shares were purchased at an average cost of $28.62 per share, for a total transaction of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $31.65, for a total value of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc purchased 6,175 shares of Sensei Biotherapeutics stock. The shares were purchased at an average cost of $34.49 per share, for a total transaction of $212,975.75.
• On Tuesday, March 31st, Millennium Management Llc purchased 6,005 shares of Sensei Biotherapeutics stock. The shares were purchased at an average cost of $28.16 per share, for a total transaction of $169,100.80.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $32.12, for a total value of $246,231.92.

Sensei Biotherapeutics Trading Up 3.1%

SNSE stock traded up $0.61 during trading on Friday, reaching $20.43. 40,084 shares of the stock were exchanged, compared to its average volume of 223,112. The firm’s 50 day moving average is $29.11 and its 200 day moving average is $17.85. Sensei Biotherapeutics, Inc. has a twelve month low of $5.25 and a twelve month high of $36.76. The firm has a market cap of $27.40 million, a P/E ratio of -1.23 and a beta of -0.18.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). As a group, analysts predict that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Finally, Leerink Partners assumed coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective for the company. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $40.00.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 10.50% of the company’s stock.

Key Headlines Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.